OncoMatch/Clinical Trials/NCT05641428
Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL
Is NCT05641428 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including ARI-0001 and Axi-cel for nhl.
Treatment: ARI-0001 · Axi-cel — A phase II, multi-center study to compare the feasibility, and clinical efficacy of local manufacturing of CD19-directed CAR T-cells (ARI-0001 CAR T-cells) with commercial produced CAR T-cells (for example axicabtagene ciloleucel, a CD19 targeting commercially available CAR T-cell) in patients with relapsed or refractory (R/R) DLBCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Performance status
ECOG/WHO 0–2
Prior therapy
Must have received: systemic therapy
R/R after at least 2 lines of systemic therapy
Lab requirements
Blood counts
ANC <1.0x10^9/L, Platelet count <50x10^9/L, Absolute lymphocyte count <0.1x10^9/L [excluded]
Kidney function
GFR <40 mL/min calculated according to the modified formula of Cockcroft and Gault or by direct urine collection [excluded]
Liver function
total bilirubin, AST and/or ALT >5 x institutional ULN, unless directly attributable to the lymphoma or Gilbert disease [excluded]
Cardiac function
Clinical heart failure with NYHA class ≥2 or LVEF <40% [excluded]
ANC <1.0x10^9/L; Platelet count <50x10^9/L; Absolute lymphocyte count <0.1x10^9/L; Clinical heart failure with New York Heart Association class ≥2 or LVEF <40%; Liver dysfunction as indicated by total bilirubin, AST and/or ALT >5 x institutional ULN, unless directly attributable to the lymphoma or Gilbert disease; GFR <40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify